Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the WT-1 vaccine causes an immune response
and is safe. The WT-1 vaccine is made up of protein pieces that the patient's immune system
can recognize as abnormal.
Phase:
N/A
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute